Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge with limited treatment options for advanced stages.
• Understanding HCC's molecular drivers is crucial for developing novel therapeutic strategies.
• Epigenetic modifications, specifically histone deacetylase (HDAC) inhibition, represent a promising avenue for cancer treatment.

Purpose of the Study:

• To review the role and therapeutic potential of histone deacetylase inhibitors (HDACi) in hepatocellular carcinoma (HCC) treatment.
• To explore the molecular mechanisms underlying HDAC inhibition's anti-tumor effects in HCC.
• To summarize preclinical and clinical findings on HDACi in HCC, including combination therapies.

Main Methods:

• Review of preclinical studies on various HDAC inhibitors (e.g., valproic acid sodium, panobinostat, vorinostat) in HCC models.
• Analysis of combination regimens involving HDAC inhibitors with other targeted therapies (e.g., sorafenib).
• Examination of clinical trial data (Phase I/II) assessing HDACi monotherapy and combination treatments in HCC patients.

Main Results:

• Preclinical studies demonstrate that HDAC inhibitors induce antitumor efficacy through cell death pathways.
• Combination therapies with HDAC inhibitors and agents like sorafenib show potential therapeutic benefits.
• Early clinical trials indicate response and survival advantages with HDAC inhibitors, alongside a manageable safety profile.

Conclusions:

• Histone deacetylase inhibitors (HDACi) hold significant therapeutic potential for hepatocellular carcinoma (HCC) treatment.
• HDACi can be effectively combined with other agents to enhance anti-tumor activity.
• Further clinical investigation of HDACi is warranted for advanced HCC management.